Latuda
| Name | LATUDA® (Lurasidone) |
| Description | LATUDA® is a once-daily oral atypical antipsychotic. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet medical needs of schizophrenia patients treated with current antipsychotics. |
| Indication | LATUDA® is indicated for the treatment of schizophrenia in adults aged 18 years and over. |
| Strengths |
18.5 mg, 37 mg and 74 mg film coated tablets |
| Regulatory Status |
FDA approved in October 2010 EMA approved in March 2014 Latuda® tablets are registered in UAE and KSA. |
| Business Partner |
Sunovion Pharmaceuticals |
